Dupilumab treatment was associated with improved bone growth and bone mineral density in children with eczema, according to a study published in the Journal of the American Academy of Dermatology.

Among infants with eosinophilic esophagitis aged younger than 1 year or weighing less than 15 kg, esophageal eosinophilia and ...

Chronic obstructive pulmonary disease patients with type 2 inflammation may soon gain access to a new drug — dupilumab — that showed rapid and sustained improvements in patients in a pivotal Phase 3 ...

Dupilumab's growth is driven by its established market presence, new indications like COPD, broad multi-indication use, and strong clinical performance. Recent approvals and phase III trial successes, ...

When people have the rare disease eosinophilic gastritis (EoG), many common foods can trigger severe stomach reactions – including dairy, wheat, gluten, egg, soy, fish and nuts. Flare-ups can strike ...

For patients with atopic dermatitis (AD), dupilumab maintains its clinical effectiveness up to five years and is discontinued by 23.8% of patients, according to a study published online Aug. 7 in JAMA ...

These improvements — as measured by a significantly lower annualized rate of acute exacerbations, significantly better lung function and quality of life, and significantly less severe symptoms than ...

Compared with dupilumab, a significantly higher proportion of patients treated with upadacitinib achieved both EASI 90 and WP-NRS 0/1 at week 16. Among patients with moderate to severe atopic ...

In May, we reported on positive phase III trial data on dupilumab (Dupixent) for uncontrolled chronic obstructive pulmonary disease, a condition with no approved biologic therapy. In this report, we ...

Dupilumab is effective for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, but a recent presentation noted the payer challenge in placing the biologic in an optimal tier. In ...